Clinical Trials Directory

Trials / Completed

CompletedNCT02457221

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
314 (actual)
Sponsor
Astellas Pharma China, Inc. · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of Tacrolimus capsules for induction remission in patients with lupus nephritis, and compare the efficacy and safety with Cyclophosphamide injections.

Detailed description

This is a randomized, open, 1:1 parallel controlled, multi-center, non-inferiority clinical study.

Conditions

Interventions

TypeNameDescription
DRUGTacrolimus capsulesoral
DRUGCyclophosphamide injectionsintravenous injection
DRUGPrednisoneoral

Timeline

Start date
2015-03-10
Primary completion
2018-09-10
Completion
2018-09-10
First posted
2015-05-29
Last updated
2024-11-01

Locations

35 sites across 1 country: China

Source: ClinicalTrials.gov record NCT02457221. Inclusion in this directory is not an endorsement.

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus N (NCT02457221) · Clinical Trials Directory